Q4: While China is expanding opening-up, some are concerned that geopolitical tensions, rising protectionism and global supply chain adjustments may weaken China's attractiveness to foreign companies. What's your take? How important will China be for your global business in the coming decade? What more opening-up measures can China take to offset the impact of the complex external environment?

LI: China is the world's second-largest pharmaceutical market and our second-largest market as well. With decades dedicated to the Chinese market, Cytiva takes accelerating localization in China as one of our key global strategies. Through localization of innovation, commercial operations, and supply chain and manufacturing, we aim to empower Chinese enterprises as their best partner to reduce costs, increase efficiency, and innovate comprehensively.

The conference emphasized the need to foster a fairer and more dynamic business environment and improve the property right protection system, and we firmly believe in this. We look forward to the continuous improvement of the business environment, which will further boost international confidence in the Chinese economy, ushering in the next wave of high-quality development in the Chinese economy.

L. WANG: The Chinese market is of high potential and rapidly growing in the past many years with its robust manufacturing capabilities, comprehensive supply chain, and stable policy environment. We have firm and long-term confidence in the market as well as in its manufacturing and innovation capability. China is now AstraZeneca's second-largest market, and it is a key engine for our future success. As a localized multinational company, AstraZeneca has been truly rooted in China for over 30 years and our presence in China covers R&D, manufacturing and production, and commercialization. We have firm confidence in the Chinese market, its economic development, manufacturing and innovation capability.

N. WANG: China's deepening reforms and expanding opening-up promise to create broader opportunities worldwide. These reform measures are pivotal not only in addressing global challenges, but also in ensuring China's continued high-quality development — a dual impact that could reshape economic dynamics both domestically and internationally. China has always been one of the most promising markets for LinkedIn. We have utilized unique business model and industry-leading big data and AI technologies to help witness countless homegrown and innovative Chinese companies venture overseas, becoming a significant presence in the global market.

ZHAO: We have seen a series of new measures and initiatives aimed at creating an institutional environment that is transparent, stable and predictable against the backdrop of global headwinds, which is appealing to foreign companies. In addition, the vast market with high unmet medical needs in underserved and serious diseases, and the country's commitment to innovation are also boosters of confidence for MNCs like Astellas.

China is one of Astellas' five global markets, ranking among the top three out of the fifteen prioritized markets for Astellas globally. We're committed to delivering innovation that makes a difference to the people of China and the healthcare systems that support them.